Trial Profile

A safety and PK/PD clinical trial for imeglimin for the treatment of type 2 diabetes (Metavant study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imeglimin (Primary)
Indications Kidney disorders; Type 2 diabetes mellitus
Focus Adverse reactions

Most Recent Events

20 Nov 2020 According to a Poxel media release, Metavant has conducted a strategic review and has decided not to move forward with the development of Imeglimin and this decision was not based on any efficacy, safety or other data generated through the partnership.
26 Mar 2020 According to a Poxel media release, Metavant met with the FDA in Q1 2020 to discuss the Imeglimin Phase 3 program in type 2 diabetes patients with CKD stages 3b/4, an underserved patient population.
31 Oct 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com